COMP <GO>
CRDF vs NMRA // OPERATING MARGIN
Cardiff Oncology Inc. (NASDAQ) VS. Neumora Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CRDF 1
— NMRA 2
■ METRIC PARITY
LAST: $0.89 (-2.46%) • MKT CAP: $70.9M
operating-margins
-60.00%
LAST: $0.37 (-5.43%) • MKT CAP: $73.0M
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRDF VS. NMRA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRDF | NMRA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -7.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -13.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | NMRA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.9 | 28.8 | +10.08 | CRDF | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $70.9M | $73.0M | -$2.0M | NMRA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRDF REV | NMRA REV | CRDF GROSS % | NMRA GROSS % | CRDF FCF | NMRA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $593.0K | $0 | — | — | -$38.0M | -$206.4M |
| FY 2024 | $683.0K | $0 | — | — | -$37.8M | -$182.9M |
| FY 2023 | $488.0K | $0 | — | — | -$30.9M | -$163.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRDF // BETA —
NMRA // BETA —